A U.S Post Approval Study Evaluating the SYNERGY XLV (MEGATRON) Stent System

Completed

Conditions studied: Atherosclerosis, Heart Diseases, Coronary, Coronary Artery Disease, Cardiovascular Diseases

In brief

This is a post-market, standard of care, real-world observational study to assess the clinical outcomes of the SYNERGY XLV (MEGATRON) Coronary Stent System for the treatment of subjects with atherosclerotic lesion(s) ≤ 28 mm in length (by visual estimate) in native coronary arteries ≥3.50 mm to ≤5.00 mm in diameter (by visual estimate). This Post Approval study is a cohort associated with the Evolve 4.5/5.0 (SYNERGY LV) Post Approval Study, which is registered under ClinicalTrials.gov ID: NCT03875651.

Key facts

Study ID

NCT04807439

Run by

Boston Scientific Corporation

People needed

100

Starts

2021-04-14

Expected to finish

2023-08-18

Last updated by the study team

2023-10-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient requires treatment with a SYNERGY XLV (Megatron) stent

You may not qualify if…

• Planned treatment with a non-SYNERGY stent

Where it is running

• Yale University — New Haven, Connecticut, United States
• Clearwater Cardiovascular Consultants — Clearwater, Florida, United States
• Beth Israel Deaconness Medical Center — Boston, Massachusetts, United States
• North Kansas City Hospital — Kansas City, Missouri, United States
• Wake Medical Center — Raleigh, North Carolina, United States
• Oregon Health Sciences University — Portland, Oregon, United States
• Baylor Heart and Vascular Hospital — Dallas, Texas, United States
• Inova Fairfax Hospital — Fairfax, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.